Health3-2-1 Selects Companies for UK & US Expansion – Strengthening Nordic & Baltic Life Science Exports

The application process for the EU funded project Health3-2-1 has successfully concluded, and the selected companies are now gearing up for their export journey! This brings us one step closer for the companies to get bigger muscles for their US and UK market expansion. A total of 46 innovative life science companies have been chosen to participate:

• 13 from Sweden - Swecare
• 22 from Finland - Business Turku
• 11 from Estonia - Tehnopol

These companies will receive funding, expert guidance, and networking opportunities to support their internationalisation. Despite challenges such as COVID-19 and Brexit, the industry has also seen new opportunities emerge. Through Health3-2-1, companies will gain valuable insights into the UK and US markets, equipping them with the tools needed to scale their businesses internationally. Health3-2-1 is designed for Medtech, Healthtech, Pharma, and Biotech SMEs in Sweden, Finland, and Estonia that are looking to expand into the UK and the East Coast of the US. In collaboration with key partners, the project provides: Market intelligence and structured training, regulatory and commercial strategy support, matchmaking with key industry stakeholders, export missions, site visits, and sales lead generation.

Value for the companies

To understand the impact of Health3-2-1, we spoke with Emma Höglund, CEO of Neobiomics, about their plans for the US market.

"We have so far established a presence in Europe with our two products for use in neonatal intensive care. A natural next step is to explore markets beyond Europe and the US is an obvious candidate with both big opportunity and challenges. We are hoping to shape our expansion strategy by accessing expert help on regulatory and commercial aspects as well as learning from peer companies in the program. Our ultimate goal is to start selling our product in the US" says Höglund.

As part of the project, Neobiomics will focus on:

• Understanding the specific medical needs of US Neonatal Intensive Care Units and how their solutions fits in.
• Learn the best regulatory pathway to secure product approval in the US.
• Set a targeted commercial strategy for the market and connect with potential partners.

With the selected companies now onboard, Health3-2-1 is set to deliver for the Nordic and Baltic life science sector. By providing the necessary tools, funding, and connections, the project will help companies navigate these markets.

For more information on Health3-2-1 and future opportunities, visit Health3-2-1 - Central Baltic.